Home
Live Updates
Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia : comparemela.com
Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia
Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX's excellent safety and tolerability profile with no untoward safety events. Novel Approach: Dopavision's
Related Keywords
Germany ,
German ,
Novartis Pharma ,
Dopavision Gmb ,
Ian Flitcroft ,
Mark Wuttke ,
Ababax Health ,
Boehringer Ingelheim Venture Fund ,
German Federal Ministry Of Education ,
Business Wire ,
Coordinating Investigator ,
With Myopiax ,
Seventure Partners ,
German Federal Ministry ,
Executive Officer ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.